List of Startups Fundraising #November 💰
From idea-stage to Series A Founders. 📣 Get exposed to over 2100 subscribers globally, most of whom are investors.
Welcome to Learning VC💡! I’m Luis Llorens and I write monthly about venture capital, investments, fundraising and my personal experiences as an investor. Subscribe for free to receive new posts and support my work:
In this post you will find a list of entrepreneurs and startups in the midst of their fundraising endeavours💰. Some of them have not yet obtained private funding and are at the outset of their journey.
In November, we got:
✅ 30 startup applications.
✅ Stages: 3% Stealth, 63% Pre-seed, 27% Seed, 7% Series A.
✅ Geographies: 77% Spain, 23% RoW.
Since we began in April, we have received over 270 startup applications.
If you want to boost your funding round, fill out THIS FORM and I will do my best to help you!
If you are a business angel or VC and want to take a look at the list of startups, leave a comment below and I will share the full list with you.
I have chosen two investment opportunities, both founded by Spanish entrepreneurs but based in different locations, and provided a brief analysis:
📍 HQ: San Francisco, USA
🏭 Industry: Healthtech, AI
☘ Stage: Seed
🚨 Problem: 30M Americans have already tried GLP-1 to lose weight but struggle to understand its effects on them.
🔛 Solution: An AI platform for GLP-1 patients to stay in control of their GLP-1 journey. Gala GLP-1 allows users to track shots, dosage absorption, predict side effects and optimize medication effectiveness. It also offers useful information about the different types of medication or the latest research on GLP-1, based on their profile.
📱 Product: GLP-1 Tracker
🫰 Business model: Gala charges a subscription to its customers. In the near future, the company plans to earn a commission on every GLP-1 medication purchase made through the platform.
🎯 Ideal Customer Profile: Patients on GLP-1 medication. 70% of the current users are in the US.
📊 Traction: $3K Revenue 1st month (oct-24), $10K revenue 2nd month (nov-24).
🏚 Market: Today, the total market for GLP-1 medication is $47B. In 8 years, the market is projected to reach $470B. Nearly 1B people will be clinically obese by 2032 and only one solution works for them (GLP-1)
👥 Fede Buldin (Co-founder) - Former AI Founder at Bookline.ai, AI Analyst at Accenture.
👥 Javi d'Erausquin (CEO) - Head of Digital Marketing for the Former Prime Minister of France, Consultant at PWC.
💰 Round: Seed round, undisclosed
📍 HQ: Berlin, Germany
🏭 Industry: SaaS 3.0, Analytics, Design
☘ Stage: Pre-seed
🚨 Problem: Access to user insights is very gated, teams struggle to leverage the data they collect.
🔛 Solution: Make insights instantly accessible by bridging design and user behaviour. Think Amplitude meets Figma.
📱 Product: Enables product teams to get user insights in seconds by simply looking at their product’s UI.
🫰 Business model: Freemium, with event-based pricing model.
🎯 Ideal Customer Profile: Product-led companies in series B and beyond.
📊 Traction: Saving existing customers 48+ hours per team/sprint. #1 Product Hunt launch with 200+ waitlist.
🏚 Market: They are entering the product analytics market by first focusing on UX/UI teams - an underserved yet critical segment of the product development process. Bottom-up calculation estimates a total of 9.6M users in our SOM as of 2024.
👥 Asís Ybarra (CEO) - Product & Data Lead, background in Design and Mathematics.
👥 Philipp Riedel (CTO) - 7+ years in Web Development and Data Science.
💰 Round: €1 million pre-seed round.
Would you consider investing in Gala or Glazed?🤔 ASK ME IF YOU WANT TO KNOW MY PERSONAL FEEDBACK (POSITIVE FACTORS & CONCERNS) ON BOTH OPPORTUNITIES❗
If you’d like to be featured in my next blog post, let me know! Help me spread the word and get in front of 2100+ subscribers.
That’s all folks — thank you for taking a look! If you liked this post, don’t forget to follow me on LinkedIn & Subscribe for free below🔔
Interested!
Interested!